Opinion

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Zimmer: the strong get stronger

Over the past few years, Zimmer [ZMH] has demonstrated even higher growth than the impressive rates seen in the overall orthopaedic market, and is now set to become even stronger with the addition of Centerpulse. The company will take market leadership position in joint reconstruction and become the fifth largest player in the lucrative sector of spinal implants.

Published By Datamonitor
20 Oct 2003
CommentWire
CommentWire

Zimmer: spinal expansion would maximize Collagraft potential

The recent approval for these indications allows Zimmer to compete in the largest segment of the $200 million US market for bone growth substitutes. However, unless the company fully enters the spinal implant market - including the establishment of a spinal salesforce - Collagraft will not reach its sales potential.

Published By Datamonitor
01 Nov 2001
CommentWire
CommentWire

Zimmer: big advances through tiny holes

Zimmer has released positive preliminary results for its two-incision minimally invasive hip arthroplasty system, and also plans to open a training facility teaching surgeons how to implant these systems. But while the system can radically reduce recovery time, it involves an extremely difficult technique that most orthopaedic surgeons are unlikely to adopt.

Published By Datamonitor
24 Jul 2002
Expert View
Expert View

Zetia: Potential to reshape the cholesterol drug landscape?

Statins have become the gold standard in the treatment of dyslipidemia, accounting for approximately 60% of treatments prescribed to patients with coronary heart disease in the late 1990s. However, with these drugs limited in their ability to lower LDL cholesterol to the target recommended by the National Institutes of Health an opportunity awaits for a therapy able to achieve this goal.<BR />

Published By Datamonitor
30 May 2003
CommentWire
CommentWire

Zeltia: opening up options for ovarian cancer

Following promising Phase II trial results, Zeltia has announced the initiation of an international Phase III clinical trial to investigate a combination of Yondelis and Caelyx. Investigating Yondelis in relapsed ovarian cancer patients theoretically allows for its use in multiple lines of treatment, thereby greatly increasing its future commercial potential.

Published By Datamonitor
05 Apr 2005
CommentWire
CommentWire

Zeltia: files for approval of Yondelis for ovarian cancer in the US

Zeltia/Johnson & Johnson are seeking US approval for Yondelis, following a pivotal Phase III trial in second-line ovarian cancer therapy. However, approval in this indication may only marginally increase the commercial potential of Yondelis, as competition from established platinum-based chemotherapy agents will restrict the drug's market potential.

Published By Datamonitor
24 Nov 2008
CommentWire
CommentWire

Zelos: osteoporosis therapy to face challenge despite positive data

Significant, dose responsive increases in mean lumbar spine bone mineral density have been recorded in a four month study of Zelos' parathyroid hormone injections for the treatment of osteoporosis. However, although perhaps indicative of future FDA approval, the positive clinical trials results do not necessarily mean Ostabolin-C will make a significant impact on the osteoporosis market.

Published By Datamonitor
09 Feb 2007
Expert View
Expert View

Zelboraf's approval demonstrates a significant shift toward personalized cancer therapy

The FDA has approved Zelboraf and Roche's companion diagnostic test for BRAF V600E mutation-positive metastatic melanoma. The joint approval is the first example of co-development and demonstrates the movement toward personalized cancer therapy, and Zelboraf's impressive efficacy data and the availability of a test will ensure rapid uptake.

Published By Datamonitor
18 Aug 2011
CommentWire
CommentWire

Zavvi: turning down the music

Entertainment retailer Zavvi has given an update on its first year of trading following the management buy-out and re-branding in September 2007. The results represent a strong comeback in tough conditions, with like-for-like sales up 10% and annual losses cut by more than GBP10 million, despite an 18% slump in music sales.

Published By Datamonitor
17 Sep 2008
Expert View
Expert View

Zavvi: facing challenges ahead

In recent years, Virgin Megastores, or Zavvi as it is now known, has struggled to break even. While the retailer has worked hard to improve profitability, continued price deflation and rising fixed costs have made this extremely difficult to achieve. Furthermore, with the music market in decline, growing the top line has also proved to be a challenge for Zavvi.

Published By Datamonitor
07 Apr 2008

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.